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Introduction: Neovascular age related macular degeneration (AMD) is relatively uncommon 
in the black population. We report the 12-month outcome of ranibizumab therapy in five black 
patients with choroidal neovascular membrane (CNV) secondary to AMD.
Material and methods: Retrospective analysis of a prospective audit database maintained 
for all patients on ranibizumab therapy in a retinal specialist unit that caters to a multi-ethnic 
cohort in London, United Kingdom.
Results: At 12 months, all the 5 patients maintained stable vision (loss of less than 15 ETDRS 
letters). However, none of them gained more than 15 ETDRS letters. All eyes showed early 
subretinal fibrosis while 2 patients showed extended areas of retinal pigment atrophy.
Conclusion: Our case studies indicate that ranibizumab stabilizes the vision in black patients 
with CNV secondary to AMD but they tend to develop early subretinal fibrosis and retinal 
pigment atrophy.
Keywords: choroidal neovascular membrane, Afro-Caribbean, blacks
Introduction
Neovascular age related macular degeneration (AMD) causes severe visual loss 
and is the most common cause of blindness in the western world.1 Population based 
epidemiological studies have shown significant variation in the prevalence of AMD 
among various racial/ethnic groups.2 Data from prevalence of AMD in 4 racial/ethnic 
groups in the multi-ethnic study of atherosclerosis suggested prevalences of AMD 
were 2.4% in blacks, 4.2% in Hispanics, 4.6% in Chinese and 5.4% in the white 
population, while estimated prevalence of late AMD were 0.3% in blacks, 0.2% in 
Hispanic, 0.6% in the white and 1.0% in the Chinese population.3 In contrast, the 
incidence of idiopathic polypoidal choroidopathy (PCV) is high among blacks, 
moderate in Asians and low in whites.4 Therefore, a high index of suspicion of both 
conditions are required when evaluating black patients with clinical presentation 
of AMD.
Ranibizumab is an inhibitor of all isoforms of VEGF-A.5 It has been shown 
to be effective in improving vision (gain of more than 15 letters) in subfoveal 
choroidal neovascularisation (CNV) secondary to neovascular AMD in several 
randomized trials in predominantly Caucasian cohorts.5,6 We report the clinical 
features and 12-month outcome of ranibizumab therapy in five black patients 
with neovascular AMD and no evidence of PCV on indocyanine angiography 
(ICGA).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Material and methods
A prospective database is maintained for all patients on 
ranibizumab therapy in the Medical Retina clinic at King’s 
College Hospital. The audit tools include demographic details, 
duration from onset of symptoms (self-reported) to first injec-
tion, time from first diagnosis at primary care to first treatment, 
baseline best corrected visual acuity (ETDRS letters), quanti-
tative and qualitative OCT findings, clinical features as noted 
by slit lamp biomicroscopy examination, lesion subtype and 
lesion size noted on fundus fluorescein angiography (FFA). 
The use of ICGA is optional in our clinic, but all the 5 patients 
in this report had ICGA to rule out PCV .
Each patient received 3 loading doses of monthly 
intravitreal ranibizumab (0.5 mg in 0.05 mL) therapy and 
then went on to an OCT guided treatment schedule. The re-
treatment criteria were a drop in visual acuity associated with 
intra-retinal or sub-retinal fluid on OCT, new or persistent 
fluid or the presence of new hemorrhage or angiographic 
evidence of increase in lesion size (FFA was done at the 
discretion of the treating clinician).
Case 1
A 71-year-old female presented with a 3-week history of 
decreased vision in the right eye. She was amblyopic in the 
left eye. The presenting visual acuity was 60 ETDRS letters 
in the right eye and 2 ETDRS letters in the left eye. Slit lamp 
biomicroscopic evaluation of the right eye revealed large 
areas of confluent soft drusen associated with a central 2 disc 
diameter area of sub-retinal fluid surrounded by hemorrhage. 
The left eye showed an optic nerve coloboma with confluent 
drusen at the posterior pole. Angiography (FFA and ICGA) 
showed a 100% classic CNV . The patient received 3 monthly 
injections of ranibizumab which stabilized her vision to 
60 letters. Reactivation was noted at the fifth month with 
fresh subretinal hemorrhage and she received 2 further injec-
tions of ranibizumab at fifth and ninth months. Since then 
her vision has remained stable at 60 letters and clinically, the 
macula remained dry with juxtafoveal subretinal fibrosis at 
12 months follow-up (Figure 3).
Case 2
A 73-year-old female presented with a four week history of 
  distorted vision in her left eye. She had a history of disciform 
scar in the right eye for the previous 5 years. The visual acu-
ity was 24 ETDRS letters in the left eye and eight ETDRS 
letters in the right eye. Slit lamp biomicroscopy showed a 
pigment epithelial detachment (PED) in the left eye of about 
2 disc diameters with extra-foveal hemorrhage. The right 
eye showed a macular disciform scar. Angiogram (FFA and 
ICGA) confirmed subfoveal occult CNV in the left eye. She 
had 3 injections of ranibizumab and her vision stabilized at 25 
letters. Reactivation of the lesion indicated by new subretinal 
fluid was noted at the sixth month follow-up (Figure 1). She 
received 2 more injections of ranibizumab at the sixth and 
seventh months. At the final follow up of 12 months, her 
vision was stable at 25 letters and the lesion was dry with 
central subretinal fibrosis (Figure 2).
Case 3
A 75-year-old male was referred from his optician with a 
history of hemorrhage at the posterior pole in the left eye. He 
had a history of disciform scar in his right eye. The presenting 
visual acuity was 45 letters in the left eye and 25 letters in the 
right eye. Examination of the left eye revealed a large area 
of juxtafoveal subretinal bleed while the right eye showed a 
macular disciform scar. Angiogram (FFA and ICG) confirmed 
the presence of a subfoveal occult CNV partly obscured by the 
hemorrhage with no evidence of IPCV . The patient received 3 
injections of ranibizumab in the left eye. His vision is stable at 
40 letters and clinically, the hemorrhage has resolved leaving 
a large area of retinal pigment epithelial atrophy and central 
subretinal fibrosis at 12 months.
Case 4
An 82-year-old male was referred from the ERS (emergency 
referral service) with history of distorted vision in the left 
eye of 3 weeks duration. He had past history of disciform 
macular scar in the right eye. His presenting visual acuity 
was 45 letters in the left eye and 40 letters in right eye. Slit 
Table 1 summary of patient characteristics
Age/Sex Presenting VA VA final Type of CNV Lesion size (DD) Number of injections Other eye
71/F 60 60 Classic 2DD 5 Amblyopia
73/F 24 25 Occult 2DD 5 Disciform 
76/M 45 40 Occult 10DD 3 Disciform 
82/M 45 45 Occult 5DD 3 Disciform
84/F 60 47 Predominantly classic 6DD 12 Disciform
Abbreviations: M, male; F, female; CnV, choroidal neovacularization; DD, disc diameters; VA, visual acuity.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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lamp biomicroscopy showed an area of 5 disc diameters of 
RPE atrophy at the posterior pole with a streak of subretinal 
juxtafoveal hemorrhage extending across the atrophic area 
in the left eye. The right eye showed a macular disciform 
scar. The angiogram (FFA and ICGA) confirmed a subfo-
veal occult CNV of about 5 disc diameters. He had three 
consecutive injections of ranibizumab in the left eye for 3 
months and was subsequently observed monthly. At 6 months 
follow-up reactivation was seen with fresh hemorrhages 
noted at the macula and he received a fourth injection of 
ranibizumab. His vision is stable at 45 letters and clinically 
an atrophic lesion with subretinal fibrosis is present at 12 
months follow up.
Case 5
An 84-year-old female presented with a history of reduced 
vision in the right eye of 2 weeks duration. She had a his-
tory of blindness in the left eye since 30 years, secondary to 
idiopathic extensive chorioretinal scarring. The presenting 
visual acuity was 60 letters in the right eye and no projection 
of light in the left eye. Slit lamp biomicroscopy showed a large 
area of confluent soft drusen extending up to the   vascular 
arcades with a central 6 disc diameter area of subretinal fluid 
with areas of subretinal hemorrhages. Angiogram confirmed 
predominantly classic CNV . The patient received 3 injections 
of ranibizumab but the lesion was still active with subretinal 
fluid on OCT scan. She continued to receive nine further 
injections monthly. She had persistent subretinal fluid and 
her vision was 47 letters at 12 months follow up.
Discussion
This study is not a population-based prevalence or incidence 
study, but a report on the number of black patients who have 
actually been treated with ranibizumab in our Medical Retina 
Clinic (Table 1). Our audit database shows that approximately 
450 persons per million populations require ranibizumab 
therapy in South East London. While these figures may be 
an underestimate due to patients presenting late or present-
ing at other units, we believe that it reflects the proportion 
of treatable patients presenting to most treatment centers in 
the UK at present.
London has a multiethnic population. Lambeth, South-
wark, and Lewisham are the three adjacent boroughs in 
inner London with a combined population of about 737,000 
(the total population of London is around 7 million) where 
25% of the population are made up of black Caribbean, 
black African and black other (n = 184,000). However, only 
16% of the black population are above 55 years. Patients 
from this area are referred to King’s College Hospital for 
secondary care.
Our audit data indicate that 5 out of 350 patients (0.014%) 
undergoing ranibizumab therapy for neovascular AMD are 
blacks. These figures suggest a prevalence data of 0.03% of 
blacks requiring ranibizumab therapy for neovascular AMD 
(these data does not include patients that present with PCV). 
This low rate of presentation may be because of the reported 
Figure 2 Case 2: Post-ranibizumab therapy: Cirrus OCT macular cube (512 × 128) 
showing sub-retinal fibrosis and foveal atrophy.
Figure 1 Case 2: Pre-ranibizumab therapy: Cirrus OCT macular cube (512 × 128) 
showing intra-retinal fluid.
Figure 3 Pre- and post-ranibizumab therapy showing increase in macular fibrosis.Clinical Ophthalmology
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low prevalence of AMD in the blacks, lower proportion of 
older blacks in these London boroughs and lack of aware-
ness of the disease.
The audit of our ranibizumab database showed that 94% 
of the patients showed stabilization of vision (loss of 15 
ETDRS letters or less) while 18% gained 15 or more ETDRS 
letters at 12 months. In comparison, the results in black 
patients suggest that although stabilization of visual acuity is 
achieved in 100%, none of the black patients gained vision. It 
is also important to note that despite the robust re-treatment 
criteria, these patients did not require many injections. 
However, subretinal fibrosis was seen in all cases from the 
third injection. In addition, extended areas of retinal pigment 
atrophy were noted in two areas. We hypothesize that exagger-
ated subretinal fibrosis and retinal pigment epithelial atrophy 
in blacks may represent part of the spectrum of increased 
tendency of hypertrophic dermatologic scars in black people. 
These scars are associated with increased serum levels of 
cytokines such as IL-6, TGF-β and TNF-α, upregulation of 
tumour suppressor gene p53 and anti-apoptotic gene Bcl-2 
and low levels of vitamin D3.7 It may be useful to study the 
role of inflammation and apoptosis related genes to better 
understand the pharmacogenetics of neovascular AMD in 
the black population.8
All the five patients also had poor vision in the other eye, 
four of them due to disciform macular scars following wet 
AMD and one due to amblyopia. The amblyopic eye also had 
confluent drusen at the macula. It is interesting to note that none 
of these patients had retinal angiomatous proliferation.
Ranibizumab was well-tolerated in this group.9 Although 
glaucoma is common in the black community, none of these 
patients had the condition or experienced post-injection 
spikes of raised intraocular pressure.10,11 However, the 
  observations in our small case series are retrospectively 
obtained,   limiting the generalization of these findings. 
These observations should prompt larger prospective 
studies to evaluate the response of this therapy in various 
ethnic groups.
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